This study is currently not recruiting participants.

A Randomized Controlled Open-Label Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

The purpose of the study is to evaluate the safety, tolerability and effectiveness of SGI-110 and any potential benefits at different doses.

Description

The purpose of the study is to evaluate the safety, tolerability and effectiveness of SGI-110 and any potential benefits at different doses.

Details
Condition Ovarian Cancer
Age 18years - 100years
Clinical Study IdentifierTX2961
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.